The challenges of measuring disability accumulation in relapsing–remitting multiple sclerosis: evidence from interferon beta treatments

References

• Compston A, Coles A. Multiple sclerosis. Lancet 359(9313), 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343(13), 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338(5), 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 28(5), 363–379 (2010).
   PubMed Web of Science ®Google Scholar
• Hughes S, Spelman T, Trojano M et al. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. J. Neurol. Neurosurg. Psychiatry 83(3), 305–310 (2012).
   PubMedGoogle Scholar
• Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 66(2), 172–177 (2006).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114(Pt 2), 1057–1067 (1991).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126(Pt 4), 770–782 (2003).
   PubMed Web of Science ®Google Scholar
• Leray E, Yaouanq J, Le Page E et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 133(Pt 7), 1900–1913 (2010).
   PubMedGoogle Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39(3), 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Reingold SC, Polman CH, Wolinsky JS. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 11(5), 467–476 (2012).
   PubMed Web of Science ®Google Scholar
• Trojano M, Paolicelli D, Tortorella C et al. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? Neurol. Clin. 29(2), 309–321 (2011).
   PubMed Web of Science ®Google Scholar
• Frischer JM, Bramow S, Dal-Bianco A et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132(Pt 5), 1175–1189 (2009).
   PubMed Web of Science ®Google Scholar
• Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61(11), 1528–1532 (2003).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Traboulsee A, Knappertz V et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 83(3), 282–287 (2012).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Reder AT, Ebers GC et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 78(17), 1315–1322 (2012).
   PubMed Web of Science ®Google Scholar
• Shirani A, Zhao Y, Karim ME et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308(3), 247–256 (2012).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11), 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112(Pt 6), 1419–1428 (1989).
   PubMed Web of Science ®Google Scholar
• Hyland M, Rudick RA. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs. Curr. Opin. Neurol. 24(3), 255–261 (2011).
   PubMedGoogle Scholar
• Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology 74(Suppl. 3), S8–S15 (2010).
   PubMed Web of Science ®Google Scholar
• Healy BC, Engler D, Glanz B, Musallam A, Chitnis T. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult. Scler. Int. 2013, 189–624 (2013).
   Google Scholar
• Ellison GW, Myers LW, Leake BD et al. Design strategies in multiple sclerosis clinical trials. Ann. Neurol. 36(Suppl.), S108–S112 (1994).
   PubMedGoogle Scholar
• Rudick RA, Lee JC, Cutter G et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch. Neurol. 67(11), 1329–1335 (2010).
   PubMedGoogle Scholar
• Rio J, Nos C, Tintore M et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann. Neurol. 52(4), 400–406 (2002).
   PubMedGoogle Scholar
• Cutter GR, Baier ML, Rudick RA et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122(Pt 5), 871–882 (1999).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Polman CH, Cohen JA et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult. Scler. 15(8), 984–997 (2009).
   PubMedGoogle Scholar
• Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology 58(8), 1294–1296 (2002).
   PubMed Web of Science ®Google Scholar
• Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-Foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult. Scler. 12(5), 594–598 (2006).
   PubMed Web of Science ®Google Scholar
• Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin. Ophthalmol. 41409–1422 (2010).
   Google Scholar
• Ontaneda D, LaRocca N, Coetzee T, Rudick R. Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures. Mult. Scler. 18(8), 1074–1080 (2012).
   PubMedGoogle Scholar
• Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult. Scler. 16(5), 588–596 (2010).
   PubMedGoogle Scholar
• Miller D, Weinstock-Guttman B, Bourdette D, You X, Foulds P, Rudick R. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a. Mult. Scler. 17(6), 734–742 (2011).
   PubMedGoogle Scholar
• Miller DM, Rudick RA, Baier M et al. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 9(1), 1–5 (2003).
   PubMedGoogle Scholar
• Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J. Neurol. 257(4), 584–589 (2010).
   PubMed Web of Science ®Google Scholar
• Putzki N, Fischer J, Gottwald K et al. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur. J. Neurol. 16(6), 713–720 (2009).
   PubMed Web of Science ®Google Scholar
• Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. Mult. Scler. 8(5), 377–381 (2002).
   PubMedGoogle Scholar
• Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 124(Pt 5), 962–973 (2001).
   PubMedGoogle Scholar
• Renoux C. Natural history of multiple sclerosis: long-term prognostic factors. Neurol. Clin. 29(2), 293–308 (2011).
   PubMedGoogle Scholar
• Berg-Hansen P, Smestad C, Sandvik L, Harbo HF, Celius EG. Increased disease severity in non-Western immigrants with multiple sclerosis in Oslo, Norway. Eur. J. Neurol. 20(12), 1546–1552 (2013).
   PubMedGoogle Scholar
• Kister I, Chamot E, Bacon JH et al. Rapid disease course in African Americans with multiple sclerosis. Neurology 75(3), 217–223 (2010).
   PubMed Web of Science ®Google Scholar
• Kantarci O, Siva A, Eraksoy M et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51(3), 765–772 (1998).
   PubMedGoogle Scholar
• Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J. Neurol. Sci. 189(1–2), 13–21 (2001).
   PubMedGoogle Scholar
• Damasceno A, Von Glehn F, Brandão CO, Damasceno BP, Cendes F. Prognostic indicators for long-term disability in multiple sclerosis patients. J. Neurol. Sci. 324(1–2), 29–33 (2013).
   PubMedGoogle Scholar
• Lević ZM, Dujmović I, Pekmezović T et al. Prognostic factors for survival in multiple sclerosis. Mult. Scler. 5(3), 171–178 (1999).
   PubMedGoogle Scholar
• Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult. Scler. 9(3), 260–274 (2003).
   PubMed Web of Science ®Google Scholar
• Myhr KM, Riise T, Vedeler C et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult. Scler. 7(1), 59–65 (2001).
   PubMedGoogle Scholar
• Riise T, Grønning M, Fernández O et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol. Scand. 85(3), 212–218 (1992).
   PubMedGoogle Scholar
• Simone IL, Carrara D, Tortorella C et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 59(12), 1922–1928 (2002).
   PubMed Web of Science ®Google Scholar
• Trojano M, Avolio C, Manzari C et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J. Neurol. Neurosurg. Psychiatry 58(3), 300–306 (1995).
   PubMedGoogle Scholar
• Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J. Neurol. Sci. 168(2), 96–106 (1999).
   PubMed Web of Science ®Google Scholar
• Binquet C, Quantin C, Le Teuff G, Pagliano JF, Abrahamowicz M, Moreau T. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis. Neuroepidemiology 27(1), 45–54 (2006).
   PubMedGoogle Scholar
• Hammond SR, McLeod JG, Macaskill P, English DR. Multiple sclerosis in Australia: prognostic factors. J. Clin. Neurosci. 7(1), 16–19 (2000).
   PubMedGoogle Scholar
• Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 113(Pt. 6), 1597–1628 (1990).
   PubMedGoogle Scholar
• Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol. Sci. 21(4 Suppl. 2), S831–S838 (2000).
   PubMedGoogle Scholar
• Uría DF, Menes BB, Calatayud MT, Arribas JM. [Prognostic factors in multiple sclerosis in a population-based series in Asturias]. Neurologia 9(5), 182–187 (1994) [ article in Spanish].
   PubMedGoogle Scholar
• Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73(20), 1616–1623 (2009).
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry doi:10.1136/jnnp-2012-304333 (2013) ( Epub ahead of print).
   PubMedGoogle Scholar
• Langer-Gould A, Popat RA, Huang SM et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch. Neurol. 63(12), 1686–1691 (2006).
   PubMedGoogle Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 129(Pt 3), 606–616 (2006).
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139), 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 57(12 Suppl 5), S3–S9 (2001).
   PubMedGoogle Scholar
• O’Connor P, Filippi M, Arnason B et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 8(10), 889–897 (2009).
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59(10), 1496–1506 (2002).
   PubMed Web of Science ®Google Scholar
• Kappos L, Traboulsee A, Constantinescu C et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67(6), 944–953 (2006).
   PubMed Web of Science ®Google Scholar
• Uitdehaag BM, Constantinescu C, Cornelisse P et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther. Adv. Neurol. Disord. 4(1), 3–14 (2011).
   PubMedGoogle Scholar
• Ebers GC, Traboulsee A, Li D et al.; Investigators of the 16-year Long-Term Follow-up Study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J. Neurol. Neurosurg. Psychiatry 81(8), 907–912 (2010).
   PubMed Web of Science ®Google Scholar
• Trojano M, Pellegrini F, Paolicelli D et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann. Neurol. 66(4), 513–520 (2009).
   PubMed Web of Science ®Google Scholar
• Kinkel RP, Kollman C, O’Connor P et al.; CHAMPIONS Study Group. im. interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66(5), 678–684 (2006).
   PubMedGoogle Scholar
• Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O’Connor PW, Simon JH. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch. Neurol. 69(2), 183–190 (2012).
   PubMedGoogle Scholar
• Kappos L, Freedman MS, Polman CH et al.; BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 8(11), 987–997 (2009).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Jones J, Li D et al. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS ONE 6(11), e22444 (2011).
   PubMedGoogle Scholar
• Bermel RA, You X, Foulds P et al. Predictors of long-term outcome in MS patients treated with interferon beta. Ann. Neurol. 73(1), 95–103 (2012).
   Google Scholar
• Uitdehaag BM, Barkhof F, Coyle PK et al. The changing face of multiple sclerosis clinical trial populations. Curr. Med. Res. Opin. 27, 1529–1537 (2011).
   PubMed Web of Science ®Google Scholar
• Rice GPA, Incorvaia B, Munari LM et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst. Rev. (4), CD002002 (2001).
   PubMedGoogle Scholar
• Gronseth GS, Ashman E. The AAN response to evidence-based medicine: promise and pitfalls. Mult. Scler. 18(7), 949–950 (2012).
   PubMedGoogle Scholar
• Greenberg BM, Balcer L, Calabresi PA et al. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol. 70(2)248251 (2013).
   Google Scholar
• Derfuss T, Kappos L. Evaluating the potential benefit of interferon treatment in multiple sclerosis. JAMA 308(3), 290–291 (2012).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Reder AT, Cutter G. Treatment with interferon beta for multiple sclerosis. JAMA 308(16), 1627–1628 (2012).
   PubMedGoogle Scholar
• Farrell RA, Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult. Scler. 13(5), 567–577 (2007).
   PubMedGoogle Scholar
• Francis GS, Rice GP, Alsop JC; PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65(1), 48–55 (2005).
   PubMed Web of Science ®Google Scholar
• Kappos L, Clanet M, Sandberg-Wollheim M et al. European Interferon Beta-1a im. Dose-Comparison Study Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65(1), 40–47 (2005).
   PubMed Web of Science ®Google Scholar
• Freedman MS, Francis GS, Sanders EA et al. University of British Columbia MS/MRI Research Group. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult. Scler. 11(1), 41–45 (2005).
   PubMedGoogle Scholar
• Knobler RL, Greenstein JI, Johnson KP et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon Res. 13(5), 333–340 (1993).
   PubMedGoogle Scholar
• Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst. Rev. (2), CD005278 (2008).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Cutter G, Baier M et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 56(5), 1324–1330 (2001).
   PubMedGoogle Scholar
• Bermel RA, You X, Foulds P et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann. Neurol. 73(1), 95–103 (2013).
   PubMed Web of Science ®Google Scholar
• Kragt JJ, Thompson AJ, Montalban X et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 70(13 Pt. 2), 1084–1091 (2008).
   PubMedGoogle Scholar
• Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 75(4), 302–309 (2010).
   PubMedGoogle Scholar
• Rudick RA, Kappos L. Measuring disability in relapsing-remitting MS. Neurology 75(4), 296–297 (2010).
   PubMedGoogle Scholar
• Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin. Ther. 31(6), 1142–1157 (2009).
   PubMedGoogle Scholar
• Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol. Assess. 6(10), 1–73 (2002).
   PubMedGoogle Scholar
• Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler. 6(2), 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Fisher E, Rudick RA, Simon JH et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59(9), 1412–1420 (2002).
   PubMedGoogle Scholar
• Cadavid D, Wolansky LJ, Skurnick J et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 72(23), 1976–1983 (2009).
   PubMed Web of Science ®Google Scholar
• Lukas C, Minneboo A, de Groot V et al. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 81(12), 1351–1356 (2010).
   PubMed Web of Science ®Google Scholar
• Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann. Neurol. 59(4), 597–605 (2006).
   PubMedGoogle Scholar
• Río J, Castilló J, Rovira A et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult. Scler. 15(7), 848–853 (2009).
   PubMedGoogle Scholar
• Horakova D, Kalincik T, Dolezal O et al. Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol. Scand. 126(6), 390–397 (2012).
   PubMedGoogle Scholar
• Sämann PG, Knop M, Golgor E, Messler S, Czisch M, Weber F. Brain volume and diffusion markers as predictors of disability and short-term disease evolution in multiple sclerosis. AJNR Am. J. Neuroradiol. 33(7), 1356–1362 (2012).
   PubMedGoogle Scholar
• Giorgio A, Stromillo ML, Bartolozzi ML et al. Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. Mult. Scler. doi:10.1177/1352458513494490 (2013) ( Epub ahead of print).
   PubMedGoogle Scholar
• Lavorgna L, Bonavita S, Ippolito D et al. Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Mult. Scler. doi:10.1177/1352458513494958 (2013) ( Epub ahead of print).
   PubMedGoogle Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346(3), 158–164 (2002).
   PubMed Web of Science ®Google Scholar
• Vaneckova M, Kalincik T, Krasensky J et al. Corpus callosum atrophy—a simple predictor of multiple sclerosis progression: a longitudinal 9-year study. Eur. Neurol. 68(1), 23–27 (2012).
   PubMed Web of Science ®Google Scholar